Clinical effect analysis of osimertinib mesylate combined with pemetrexed disodium and carboplatin in treatment of advanced non-small cell lung cancer
Li Xiaoxue
Tan Xiaogang
Yao Shuyang
Nong Jingying
Zhang Yi
Abstract：Objective To investigate the clinical effect analysis of osimertinib mesylate combined with pemetrexed disodium and carboplatin in treatment of advanced non-small cell lung cancer(NSCLC).Methods Totally 105 patients with advanced NSCLC admitted to Xuanwu Hospital Capital Medical University from October 2018 to January 2023 were selected.According to the random number table method,they were divided into control group(52 cases)and observation group(53 cases).The control group received chemotherapy with pemetrexed disodium and carboplatin,while the observation group received treatment with osimertinib mesylate on the basis of the control group.Both groups were treated for 2 courses,with 3 weeks as a course.After treatment,disease control rate evaluation was conducted,and the Karnofsky performance status(KPS)score,CD3+,CD4+levels,CD4+/CD8+ratio,cytokeratin 19 fragments(CYFRA21-1),carcinoembryonic antigen,thymidine kinase 1 levels before and after treatment,and incidence of adverse reactions during treatment was compared between the two groups.Results The disease control rate in the observation group was higher than that in the control group[83.0％(44/53)vs 65.4％(34/52)](P＜0.05).After treatment,the KPS score in the observation group was higher than that in the control group[(76±6)vs(64±6)];the levels of CD3+,CD4+,and CD4+/CD8+ratio in the observation group were higher than those before treatment and higher than those in the control group;the levels of CYFRA21-1,carcinoembryonic antigen,and thymidine kinase 1 in the two groups were lower than those before treatment,and the observation group was lower than the control group(all P＜0.05).During the treatment period,there was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group[13.2％(7/53)vs 9.6％(5/52)](P＞0.05).Conclusions The clinical effect of osimertinib mesylate combined with pemetrexed disodium and carboplatin in treatment of advanced NSCLC is significant,which can significantly improve the quality of life and immune function,and has good safety.
Keywords：Advanced non-small cell lung cancerOsimertinib mesylatePemetrexed disodiumCarboplatinEfficacy
Publication Date：2024-02-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 193-197 )